Latest News for: hifu

Edit

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement ...

Nasdaq Globe Newswire 16 Jun 2026
FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical ... .
Edit

FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer

The Eagle-Tribune 16 Jun 2026
FocalTherics™ Expands Access to Focal One® Robotic HIFU for Veterans with Prostate Cancer through Agreement with MellingMedical ... .
Edit

Sonire Therapeutics Completes Enrollment in SUNRISE-I Randomized Controlled Trial of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer

PR Newswire 01 Jun 2026
Pivotal Japan-based study evaluates efficacy and safety of non-invasive HIFU system in pancreatic cancer, complementing ongoing U.S ... HIFU therapy represents an innovative approach that is distinct from existing treatments.
Edit

EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in

Hastings Tribune 14 May 2026
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq. EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited (“Telix”) to explore joint clinical research ... .
Edit

EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue

Nasdaq Globe Newswire 07 May 2026
, May 07, 2026 (GLOBE NEWSWIRE) --. EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue ... .
Edit

EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue (Form 8-K) (Edap TMS SA)

Public Technologies 07 May 2026
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue. Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth · 78% Growth in First Quarter HIFU Revenue Year-Over-Year ... HIFU Procedures Year-Over-Year.
Edit

Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer

Albany Democrat Herald 02 May 2026
SUNRISE-II feasibility trial marks the company's entry into U.S. clinical development, advancing ....
Edit

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One� Robotic HIFU in ...

Nasdaq Globe Newswire 30 Apr 2026
, April 30, 2026 (GLOBE NEWSWIRE) --. EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One� Robotic HIFU in Radiorecurrent Prostate Cancer ... .
Edit

EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer (Edap TMS SA)

Public Technologies 30 Apr 2026
EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer ... Today, the NCCN guidelines recommend HIFU as a treatment option for patients with recurrence in the prostate.
  • 1

Article Search

tools
×
×
×
×